Oct 29, 4:05 PM ET
Healthcare Realty reported third quarter 2026 results on October 29, 2026, with Normalized FFO of $0.42 per diluted share, up from $0.41 a year earlier, and a GAAP net loss of $(0.05) per share, narrower than the $(0.17) loss in the prior-year quarter. The company raised its full-year 2026 Normalized FFO guidance to $1.65-$1.67 per share from $1.62-$1.66 and raised its Same Store Cash NOI growth guidance to 5.00%-5.25%. Third quarter revenue fell to $286.6 million from $297.8 million a year earlier.
- Q3 2026 Normalized FFO of $0.42 per diluted share, versus $0.41 in Q3 2025; NAREIT FFO of $0.38 versus $0.34
- Q3 2026 GAAP net loss attributable to common stockholders of $15.8 million, or $(0.05) per share, versus $57.7 million, or $(0.17) per share, a year earlier
- Full-year 2026 Normalized FFO guidance raised to $1.65-$1.67 per share from $1.62-$1.66 in July
- Quarterly common dividend of $0.24 per share, payable November 20, 2026, to holders of record on November 10, 2026
Read the filing on SEC.gov ↗
Jul 30, 4:05 PM ET
Healthcare Realty reported second quarter 2026 total revenues of $281.8 million, down from $297.5 million a year earlier, and a GAAP net loss of $43.5 million, or $(0.13) per share, narrowed from $(0.45) a year earlier. Normalized FFO was $0.41 per share, flat with the prior-year quarter, and the company raised its full-year Normalized FFO guidance, but it lowered its full-year GAAP earnings per share guidance.
- Q2 2026 total revenues were $281.8 million, versus $297.5 million in Q2 2025; GAAP net loss attributable to common stockholders was $43.5 million, or $(0.13) per share, versus $(0.45) per share a year earlier.
- Normalized FFO was $0.41 per share, unchanged from Q2 2025; NAREIT FFO was $0.36 per share, up from $0.34.
- 2026 Normalized FFO guidance rose to $1.62 to $1.66 per share from $1.59 to $1.65; earnings per share guidance moved to $(0.15) to $(0.11) from $(0.05) to $0.05.
- The board approved a $0.24 per share dividend payable August 26, 2026, to holders of record on August 11, 2026.
Read the filing on SEC.gov ↗
May 19, 4:27 PM ET
Healthcare Realty Trust and its operating partnership entered into a $400.0 million senior unsecured delayed draw term loan facility with Wells Fargo Bank as administrative agent, dated May 15, 2026. No borrowings were outstanding at closing, and the company can draw in up to three additional draws until the first anniversary of the closing date. The filing gives shareholders a committed source of borrowing with a scheduled maturity of May 15, 2029, and an accordion option for up to $100.0 million more.
- Facility size: $400.0 million senior unsecured delayed draw term loan, with an accordion feature for up to an additional $100.0 million
- Scheduled maturity: May 15, 2029; no borrowings outstanding as of the closing date
- Agreement includes customary financial covenants, including leverage and coverage ratio requirements
Read the filing on SEC.gov ↗
May 7, 4:21 PM ET
Healthcare Realty Holdings, L.P., a subsidiary of Healthcare Realty Trust, issued $700 million of 3.00% exchangeable senior notes on May 7, 2026, including $100 million from the initial purchasers' full exercise of their option. The company fully and unconditionally guaranteed the notes, which are senior and unsecured, so the debt adds to the company's obligations for shareholders to consider.
- Total principal of $700 million, including $100 million from the full exercise of the initial purchasers' option; notes mature January 15, 2032
- Interest of 3.00% per year, paid semi-annually on January 15 and July 15, starting January 15, 2027
- Initial exchange price of approximately $23.01 per share, equal to 43.4660 shares per $1,000 principal; the issuer may settle exchanges in cash or in cash and common stock
- Company agreed to file a resale registration statement, with an effectiveness deadline of 180 days after the notes were first issued
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
